Announcing Dr. Callisia Clarke as the Skin Disease-Oriented Team (DOT) Leader
Announcing Dr. Callisia Clarke as the Skin Disease-Oriented Team (DOT) Leader. Dr. Clarke completed a master’s degree in Clinical and Translational Research in 2019. As a well-published researcher with over 60 peer-reviewed publications, she is a motivated researcher with nearly a decade of experience with clinical and translational research across several diseases. Dr. Clarke has been invested in developing the melanoma program into a regional center of excellence. She has a keen interest in developing quality/value initiatives and advancing the clinical trials portfolio in the Skin DOT and will embrace leadership of this DOT with collegiality, energy, and enthusiasm.
As DOT Leader, Dr. Clarke will meet regularly with the physicians, advanced practice providers, nurses, coordinators, and others in the disease team to increase program growth and expansion, deliver high quality, inter-disciplinary patient-oriented care, integrate translational and clinical research, and develop strategies to improve efficiency and value. She will continue to be a strong champion of clinical and translational research as the Skin DOT Chair. She will work together with Cancer Center and Service Line leadership on these important objectives.
Dr. Clarke will also be a member of the DOT Leadership Committee, which includes all DOT Leaders and representatives from Pathology, Diagnostic and Interventional Radiology, Palliative Care, and service line and Cancer Center leadership. This meeting is a forum to discuss issues of importance across all the DOTs.